Answers are grounded in this paper and cite their sources.
Non-cirrhotic extrahepatic portal vein obstruction (EHPVO) is a hepatic vascular disorder characterized by the obstruction of the extrahepatic portal vein with or without the involvement of the intrahepatic portal veins or the splenic or superior mesenteric vein in the absence of cirrhosis.1 In most cases, EHPVO leads to the development of portal cavernoma. EHPVO is commonly complicated with portal hypertension; in fact, a study revealed that 30% of patients with portal hypertension-related variceal bleeding are ultimately diagnosed with EHPVO. In addition, EHPVO is the most common cause of upper gastrointestinal bleeding in children, accounting for approximately 70% of pediatric portal hypertension cases.2 The causes of EHPVO mainly include prothrombotic states (inherited or acquired) and local factors (trauma, injuries, and inflammatory conditions). In children, the most common prothrombotic states are methylenetetrahydrofolate reductase deficiency (C677T) and prothrombin gene mutation (G20201A); in adults, the most common causes of EHPVO are myeloproliferative neoplasms (MPNs). Local factors include local abdominal inflammation and traumatic or iatrogenic neoplastic and portal vein injuries. Furthermore, rare congenital and developmental anomalies, such as portal vein stenosis, atresia, and agenesis, can lead to EHPVO.1 Patients with non-cirrhotic EHPVO usually present with prehepatic or presinusoidal portal hypertension. Generally, such patients have normal liver function and show no increase in intrahepatic resistance. In cases of persistent abnormal findings on hepatic imaging or liver examinations, liver biopsy, hepatic venous pressure gradient (HVPG) measurement, and transient elastography are recommended for liver stiffness measurement to rule out cirrhosis or porto-sinusoidal vascular disease.3 Anticoagulation therapy is a consentaneous approach required for the management of non-cirrhotic EHPVO.3 A study revealed that the course of varices in EHPVO appears to be similar to that in cirrhosis.2 Therefore, the treatment recommendations for patients with cirrhosis may be applied to patients with EHPVO. In patients with acute portal hypertension-related bleeding, blood volume restitution should be initiated to restore and maintain hemodynamic stability; furthermore, a 2–5-day course of vasoactive drugs (terlipressin, somatostatin, and octreotide) should be initiated as soon as possible. After hemodynamic resuscitation, upper endoscopy should be performed within 12 h of presentation. After they recover from acute variceal bleeding, measures for secondary prophylaxis of variceal bleeding should be implemented; the first-line option for this is a combination of non-selective beta blockers and endoscopic treatment.3 Interventional therapies also play a pivotal role in the treatment of non-cirrhotic EHPVO-related portal hypertension; these therapies mainly include percutaneous portal vein recanalization (PVR), placement of a transjugular intrahepatic portosystemic shunt (TIPS), and a combination of PVR and TIPS (PVR-TIPS). The choice of interventional therapies depends mainly on the patency of the portal outflow (comprising the intrahepatic portal vein branches) and inflow (comprising the splenic vein and superior mesenteric vein) tracts. Marot et al.4 reported that in patients who underwent PVR for non-cirrhotic EHPVO, more than 90% of the stents could maintain patency after PVR if the first- or second-degree branches of the portal vein remained unobstructed. However, PVR failure or early stent thrombosis occurred in 100% of the patients if the first- and second-degree branches of the portal vein were occluded. Thus, PVR can be recommended when the first- or second-degree branches of the portal vein are unobstructed. A previous study has reported the placement of a TIPS for the treatment of EHPVO-related portal hypertension without patient selection.5 While the study demonstrated the positive effects of a TIPS, we believe that some patients in these studies only required PVR to achieve the same efficacy and avoid the risk of TIPS-related hepatic encephalopathy and hepatic impairment. PVR is feasible in most patients with non-cirrhotic, non-tumoral EHPVO when the occlusion has not extended to the distal branches.6 However, PVR is meaningless when the first- or second-degree branches are occluded and the outflow is consequently insufficient; in such cases, TIPS placement could be considered. A randomized controlled trial has shown that a TIPS can not only effectively reduce the pressure in the portal vein but also play a significant role in portal vein thrombosis resolution.7 However, the placement of a TIPS requires the availability of portal inflow and outflow tracts; if the entire tract of the main portal vein is occluded, achieving portal vein puncture through the transjugular access during the TIPS procedure may be difficult. In such cases, PVR-TIPS may be helpful for PVR and puncture. However, the PVR-TIPS procedure is complex and associated with a high risk of complications. Therefore, it should only be performed at specialized centers wherein practitioners are highly experienced in the execution of the procedure. In recent cases wherein the PVR-TIPS approach was implemented successfully, EHPVO-related portal hypertension bleeding was controlled effectively and portal vein thrombosis was either ameliorated or completely resolved.6 Gastric varices (GVs) are more common in patients with EHPVO than in those with cirrhosis.1 In patients who have recovered from type 1 gastroesophageal varices or type 1 isolated GV bleeding, TIPS placement or balloon-occluded retrograde transvenous obliteration (BRTO) is recommended as the first-line treatment for preventing rebleeding.3 BRTO is performed by inserting a balloon catheter into a spontaneous portosystemic shunt (a gastric–renal or a gastric–inferior vena caval shunt), which subsequently blocks the blood flow; this is followed by the injection of a sclerosant directly into GVs. A meta-analysis comparing BRTO and TIPS placement in patients with GVs revealed that BRTO was associated with lower rates of rebleeding, postprocedure hepatic encephalopathy, and 1-year mortality.8 If both outflow and inflow tracts are completely blocked, it is impossible to recanalize the portal vein using the above-mentioned interventional methods. In such cases, other interventional approaches, such as partial splenic embolization (PSE), could be taken into consideration. PSE has been used in cirrhosis patients with splenomegaly or hypersplenism to reduce portal inflow, thereby reducing portal pressure. One study found that PSE could reduce HVPG; another study demonstrated that PSE could help control variceal bleeding. MPNs are usually associated with extensive splanchnic vein thrombosis; in difficult clinical scenarios wherein TIPS placement cannot be performed, PSE might be an effective strategy.9 Moreover, it is worth mentioning that ruxolitinib (a Janus kinase 1/2 inhibitor) is effective against MPN-associated splenomegaly and other constitutional symptoms and can help improve the quality of life of patients.10 Overall, interventional therapy is an effective treatment for non-cirrhotic EHPVO-induced portal hypertension, and appropriate interventional strategies must be developed based on the patency of the inflow and outflow tracts. Bin Xiong: conceived and designed the study. Jiacheng Liu and Yaowei Bai: drafted the manuscript. Bin Xiong: revised the final manuscript. All authors have read and approved the final manuscript. The authors would like to thank all colleagues for helping us during the current study. This work was funded by the National Natural Science Foundation of China (81873917). The authors declare no conflict of interest. This study had approval from the Institutional Review Board of Wuhan Union Hospital, and study procedures were performed in accordance with the Declaration of Helsinki's ethical principles. The requirement of informed consent was waived. No datasets were generated/analyzed during the current study.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: